Quarterly report [Sections 13 or 15(d)]

Significant Agreements (Details)

v3.26.3
Significant Agreements (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended
Feb. 01, 2023
Jul. 14, 2022
Jul. 13, 2021
Oct. 31, 2017
Sep. 30, 2018
Sep. 30, 2026
Jun. 30, 2026
Mar. 31, 2026
Sep. 30, 2025
Jun. 30, 2025
Mar. 31, 2025
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2021
Feb. 28, 2023
Aug. 31, 2022
Significant Agreements [Line Items]                                
Agreement due payments       $ 1,650                        
Second clinical trial payment       $ 50,000                        
Net sales percentage       2.00%                        
Common stock value           $ 5,187 $ 14,439 $ 19,569 $ 26,332 $ 9,538 $ 2,707          
Anti-dilution shares of common stock (in Shares)           19,167,878     18,796,272     19,167,878 18,796,272      
Milestone payments $ 3,700                              
Lotus International Pte Ltd [Member]                                
Significant Agreements [Line Items]                                
Sublicense income percentage                       20.00%        
Lee’s Pharmaceutical (HK) Limited [Member]                                
Significant Agreements [Line Items]                                
Significant payment received   $ 1,000                            
Milestone payments   $ 1,000                            
Lotus International Pte Ltd [Member]                                
Significant Agreements [Line Items]                                
Significant payment received $ 700                              
Shilpa Medicare Ltd [Member]                                
Significant Agreements [Line Items]                                
Payment amount                       $ 4,500        
Exclusive license agreement [Member]                                
Significant Agreements [Line Items]                                
Agreement due payments       $ 50,000                        
Spectrum Agreement [Member]                                
Significant Agreements [Line Items]                                
Issued of common shares (in Shares)         31,366                      
Common stock value         $ 4,000                      
Public market capitalization     $ 50,000   $ 50,000                      
Research and development expenses                           $ 2,200    
Sublicense income granted percentage                           40.00%    
Sublicense income percentage                           20.00%    
Spectrum Agreement [Member] | Common Stock [Member]                                
Significant Agreements [Line Items]                                
Anti-dilution shares of common stock (in Shares)     43,838                          
Spectrum Agreement [Member] | Investment [Member]                                
Significant Agreements [Line Items]                                
Interest on ownership         4.00%                      
Spectrum Agreement [Member] | Altair Nanomaterials, Inc [Member]                                
Significant Agreements [Line Items]                                
Required to pay                           $ 200    
Spectrum Agreement [Member] | Altair [Member]                                
Significant Agreements [Line Items]                                
Required to pay                           $ 4,500    
Sublicense Development Agreement [Member]                                
Significant Agreements [Line Items]                                
Significant payment received                             $ 700 $ 1,000
Minimum [Member]                                
Significant Agreements [Line Items]                                
Royalties percentage   7.00%                            
Maximum [Member]                                
Significant Agreements [Line Items]                                
Royalties percentage   10.00%